Stephan Emmerth

Stephan Emmerth

PhD | Director Therapeutic Innovation and BaseLaunch

Tel. +41 61 295 50 17

report Life Sciences
Research (Img:

Research (Img:


Cellestia compound enters into clinical development

The Basel-based biotechnology company Cellestia has received approval for the first clinical trial on its compound CB-103. The clinical trial will be open to patients with solid tumours and haematological malignancies.

Cells react to external signals through NOTCH signalling pathways. When these signal pathways are damaged, NOTCH-dependant cancers such as leukaemia, lymphoma and solid tumours can develop. Cellestia developed CB-103 as a pan-NOTCH inhibitor to treat NOTCH-positive cancers by influencing these pathways.

The Basel-based company has now received full approval from the Spanish authorities for the first clinical trial Phase I-IIa in patients with solid tumours and haematological malignancies.

According to Cellestia’s Chief Medical Officer, Dirk Weber, they are currently no approved NOTCH-targeting agents on the market for this defined patient group, giving them a generally poor survival prognosis.

Michael Bauer, CEO of Cellestia, called reaching the clinical development stage a “major milestone” for the company.

Cellestia Biotech was founded in 2014 as a spin-off from the École polytechnique fédérale de Lausanne (EPFL). It specialises in development agents that target NOTCH signalling pathways. CB-103 is its most advanced programme to date.


Life Sciences
Cookies uses cookies to ensure you get the best service on our website.
By continuing to browse the site, you are agreeing to the use of cookies.